JAJerome Aupy

Jerome Aupy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jerome Aupy has a total of 211 co-authors. Here are the top co-authors by number of shared publications:

  • Pierre Burbaud

    Department of Neuroscience, Bordeaux University, CNRS, IMN, UMR 5293 , 33000 Bordeaux

    4 shared publications
  • Bastien Ribot

    Department of Neuroscience, Bordeaux University, CNRS, IMN, UMR 5293 , 33000 Bordeaux

    3 shared publications
  • Dominique Guehl

    Univ. Bordeaux, CNRS, IMN, UMR 5293, F-33000, Bordeaux, France; CHU de Bordeaux, Department of Clinical Neurophysiology, 33076, Bordeaux, France

    3 shared publications
  • Juan Bulacio

    Cleveland Clinic, Neurological Institute, Epilepsy Center, Cleveland, OH, USA

    3 shared publications
  • A. Gradel

    CHU de Bordeaux, Department of Clinical Neurosciences, F-33000 Bordeaux, France

    2 shared publications
  • Anne-Laurie Pinto

    French Reference Centre on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, hôpital neurologique, Bron, France

    2 shared publications

Latest Publications

  • Open Access

    Electrical stimulation mapping of the visual cortex for epilepsy surgery

    by Jacques Jonas, Jérôme Aupy, Ana Maria Petrescu, Marion Marchive, Suzanne Perguilhem, Victoria Guinet, Virginie Laguitton, Véronique Sabadell, Mathilde Chipaux, Marie-Thérèse Dangles


  • Rôle du striatum dans la physiopathologie des épilepsies focales : un modèle translationnel de l’Homme au primate non-humain

    by Jérôme Aupy

    Contexte : […], le mode d'interaction entre les signaux corticaux et striataux reste flou. Dans la présente thèse, nous avons d’abord saisi l’opportunité d’enregistrements stéréoélectroencéphalographiques chez des patients atteints d’épilepsie pharamcorésistante pour analyser qualitativement et quantitativement l’activité ictale du striatum. Deuxièmement, nous avons créé un modèle primate de crises motrices focales sous-corticales induites par des injections striatales antagonistes GABAergiques. Première étude : Patients et méthode : onze patients ayant subi une évaluation SEEG ont été inclus prospectivement s'ils remplissaient deux critères d'inclusion: i) au moins un contact explorait le striatum, ii) au moins deux crises avaient été enregistrées. Les régions d'intérêt corticales et sous-corticales ont été définies et différentes périodes d'intérêt ont été analysées. Les signaux SEEG ont été inspectés visuellement et une analyse de corrélation non linéaire h2 a été réalisée pour étudier la connectivité fonctionnelle entre les régions corticales d’intérêt et le striatum. Résultats : Deux patterns principaux d'activation striatale ont été enregistrés : le plus fréquent était caractérisé par une activité alpha / bêta précoce débutant dans les cinq premières secondes suivant le début de la crise. Le second était caractérisé par une activité thêta / delta tardive plus lente. Une différence significative des indices de corrélation h2 a été observée au cours de la période préictale et début de crise par rapport au tracé de fond pour l'indice striatal global, l'indice mésio-temporal / striatal, l'index latérotemporal / striatal, l'index insulaire / striatal, l'index préfrontal / striatal. En outre, une différence significative des indices de corrélation h2 a été observée pendant la période de fin de crise par rapport à toutes les autres périodes d’intérêt. Deuxième étude : Matériel et méthode : Des injections antagonistes aiguës de GABAergic (bicuculline) ont été réalisées sur trois Macaca fascicularis dans la partie sensorimotrice du striatum. Les modifications comportementales ont été enregistrées et scorées selon une échelle de Racine modifiée. L'électromyographie, l'électroencéphalographie, les potentiels de champ locaux des noyaux gris centraux ont été enregistrés au cours de chaque expérience. Une analyse de retromoyenage a été effectuée pour chaque session enregistrée. Résultats: sur les 39 injections de bicuculline, 29 (74,3%) ont produit des changements comportementaux reproductibles caractérisés par des secousses myocloniques répétitives et pseudopériodiques avec des crises tonico-cloniques généralisées. Les injections de NaCl n'ont jamais entraîné de changement de comportement. Les secousses myocloniques étaient clairement détectables sur le signal EMG sous la forme d'une courte bouffée stéréotypée concomitante de pointes épileptiques anormales enregistrées sur l'EEG. Une analyse de rétromoyennage à partir des myoclonies EMG a montré que l'activité électrophysiologique commençait significativement plus tôt dans le striatum (p <0,0001), le GPe (p <0,0003) et le GPi (p <0,0086) que dans le cortex. Conclusion : Ces modifications du niveau de synchronisation entre les activités corticales et striatales pourraient s’inscrire dans un mécanisme endogène contrôlant la durée des oscillations anormales au sein de la boucle striato-thalamo-corticale et, de fait leur terminaison. Les interneurones GABAergic de type fast-spiking pourraient jouer un rôle crucial dans la synchronisation du réseau cortico-striato-thalamique et une modification GABAergique brutale du striatum peut provoquer une crise focale. Le rôle joué par les noyaux gris centraux dans le renforcement des mécanismes sous-jacents à la cessation de la propagation ictale devrait inspirer de nouveaux schémas de stimulation cérébrale profonde chez les patients atteints d'épilepsies focales pharmacorésistantes non chirurgicales.

  • Open Access

    Deep brain stimulation of the thalamus for intractable epilepsy (FRANCE study): A randomized clinical trial

    by Stéphan Chabardès, Fabrice Bartolomei, Anca Nica, Claire Haegelen, Lorella Minotti, Brigitte Piallat, Chrystele Mosca, Sandrine Massicot, Sylvain Rheims, Marc Guenot, et al.

    Objective: This study was undertaken to evaluate the efficacy and safety of deep brain stimulation (DBS) of the anterior nucleus of the thalamus (ANT) compared with best medical treatment (BMT) in patients with drug‐resistant epilepsy (DRE). Methods: This randomized, open‐label, phase 3 controlled trial was conducted across 14 specialized epilepsy and DBS centers. Eligible participants were adults with focal or multifocal DRE who had previously failed vagus nerve stimulation (VNS). Sixty‐one patients were randomized 1:1 either to receive continuous bilateral ANT‐DBS ( n = 30) or to continue BMT, including VNS ( n = 31), for 12 months. Afterward, patients in the BMT group were offered delayed ANT‐DBS and followed for an additional year. The primary outcome was the change in monthly severe seizure frequency (defined on the modified Chalfont Scale) at 12 months. Safety outcomes were also recorded. Results: Among 67 screened patients, 61 were enrolled. At 12 months, median seizure reduction was greater in the DBS group (−44%, interquartile range [IQR] = −67 to 0) versus the BMT group (−6%, IQR = –56 to 20; p = .09); 44.5% of patients in the DBS group achieved a ≥50% reduction in seizure frequency compared to 27% in the BMT group. Within‐group analyses showed significant seizure reductions in the DBS group at both 12 months (−44%, p < .001) and 24 months (−46%, p < .001), as well as in the delayed DBS group at 12 months (−36%, IQR = –73 to −4; p < .001). No significant differences in quality of life were observed between groups, and no major DBS‐related adverse events were reported. Significance: Our study suggests a potential benefit rather than demonstrating superiority of ANT‐DBS over medical therapy. However, within‐group improvements and favorable safety profile support the use of ANT‐DBS as a palliative treatment option in patients with DRE who have failed VNS.


  • Intra-putaminal muscarinic receptor agonist infusion induces a dystonic phenotype in non-human primates

    by Bastien Ribot, Edouard Courtin, Marc Deffains, Jérôme Aupy, Sandra Dovero, Nathalie Biendon, Tho Hai Nguyen, Hugues Orignac, Pierre Burbaud, Dominique Guehl

    Dystonia is a debilitating motor disorder of unclear pathophysiology, for which no specific pharmacological treatment is available in most cases. So far, several genetic models of dystonia suggesting a potential dysregulation of the intrastriatal cholinergic system have been obtained in rodents. However, in most cases, these animals did not exhibit a clear phenotype of dystonia but less specific motor impairments. In this study, we engineered an original model of dystonia in non-human primates by increasing cholinergic tone in the sensorimotor striatum. Chronic infusion of oxotremorine, a non-selective muscarinic agonist, into the putamen of non-human primates led to abnormal postures and dystonic movements, supported by EMG recordings. These motor abnormalities were associated with striatal hypermetabolism and significant changes in the firing rate of external and internal pallidum neurons. Furthermore, the pattern of neuronal activity in the internal pallidum was disrupted, and low-frequency oscillatory activity emerged in local field potentials within this structure. These data directly demonstrate, for the first time, in non-human primates that putaminal cholinergic dysregulation plays a crucial role in the pathophysiology of dystonia by disrupting both striatopallidal pathways.


  • Open Access

    GABRA2‐related encephalopathy: Identification of two phenotypes with distinctive electroclinical features

    by Marie Adamo‐Croux, Chloé Angelini, Jérôme Aupy, Laurent Villard, Nathalie Villeneuve, Arnaud Chefdor, Yorsa Halleb, Maxime Colmard, Manon Degoutin, Gaetan Lesca, et al.

    Pathogenic variants in γ‐aminobutyric acid type A (GABAA) receptor subunit genes are increasingly associated with epilepsy and neurodevelopmental disorders. Pathogenic variants in GABRA2, encoding the α‐2 subunit of GABAA receptors, have been recently reported. This study aims to better delineate the phenotypic spectrum of GABRA2 pathogenic variants. We conducted a retrospective multicenter study, analyzing six new patients with GABRA2 pathogenic variants identified through a French national collaboration. Clinical, electroencephalographic (EEG), and genetic data were reviewed alongside a literature analysis of eight previously reported cases. Two distinct electroclinical phenotypes were identified. The most severe, in four of six patients, featured early infantile developmental and epileptic encephalopathy with an EEG pattern of rapid rhythms suggestive of GABAergic hyperactivity. The milder phenotype, in two of six patients, included later onset, drug‐responsive epilepsy with moderate developmental delay. A literature review confirmed these phenotypes and supported genotype–phenotype correlations, with transmembrane domain variants more frequently associated with severe phenotypes. This study refines the phenotypic spectrum of GABRA2‐related disorders, highlighting two distinct electroclinical phenotypes. The identification of a recognizable EEG pattern of unusual rapid rhythms for age may be a biomarker for early diagnosis of a severe phenotype and suggests a potential underlying gain‐of‐function mechanism, to be confirmed by functional studies.


  • Striatal interdependencies in focal seizures: Insights from stereoelectroencephalographic functional connectivity analysis

    by Léa Chibany, Elena Nicollin, Edouard Courtin, Claire Bar, Véronique Michel, Guillaume Penchet, Jérôme Aupy

    Objective: We investigated the interdependency between striatal activity and the electrophysiological dynamics of the cortical epileptogenic zone using intracerebral stereoelectroencephalographic recordings in patients with drug‐resistant epilepsy. We performed both qualitative and quantitative analyses of ictal striatal activity and its synchronization with the cerebral cortex to gain deeper insight into the striatal contribution to seizure regulation. Methods: Thirty‐one patients were retrospectively included. The Epileptogenicity Index (EI) was computed, high EI values corresponded to structures in the epileptogenic zone (EZ), and brain regions with sustained discharge during the seizure were defined as the propagation zone network (PZN). To study the functional and directed connectivity between the striatum and the broader network, a nonlinear correlation coefficient ( h 2 ) and an index Dᵪᵧ that provides quantitative information about the direction of couplings between neuronal populations were computed. Results: We analyzed 31 subjects and 68 seizures. We found that 84% ( n = 57) of seizures spread to the ipsilateral striatum. This spread was mainly late during seizure evolution (69.12%, n = 47) and was mostly present in seizures characterized by a focal slow spread pattern (33.82%, n = 23). Striatal epileptogenicity was overall low, with only 4.41% ( n = 3) of seizures exhibiting a striatal EI ≥ .4. Interestingly, the positive correlation between striatal epileptogenicity and the PZN ( r = .4193, p = .0004) indicates that higher striatal epileptogenicity is associated with the recruitment of a greater number of brain regions within the PZN. Moreover, striatal functional connectivity with the broader network was the lowest during the background period and progressively increased during ictal and postictal phases ( p < .001), with directed connectivity shifting from the EZ to the striatum in the preictal and termination phases. Significance: These findings provide a framework for future research investigating the potential of basal ganglia‐targeted therapies in epilepsy management.

  • Prevalence and correlates of alexithymia in drug-resistant epilepsies

    by O. Paradas, S. Pradier, M. Decilap, A. Viaud, L. Chibani, M. De-Montaudouin, A. Gradel, V. Michel, J. Aupy


  • Top Cited Papers
    Open Access

    Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study

    by Antonio Farina, Macarena Villagrán-García, Anthony Fourier, Anne-Laurie Pinto, Fatima Chorfa, Noémie Timestit, Tifanie Alberto, Jérôme Aupy, Marie Benaiteau, Cristina Birzu, et al.


  • Open Access

    Comparative Study of Paraneoplastic and Nonparaneoplastic Autoimmune Encephalitis With GABA B R Antibodies

    by Florian Lamblin, Jeroen Kerstens, Sergio Muñiz-Castrillo, Alberto Vogrig, David Goncalves, Veronique Rogemond, Geraldine Picard, Marine Villard, Anne-Laurie Pinto, Marleen H. Van Coevorden-Hameete, et al.

    While patients with paraneoplastic autoimmune encephalitis (AE) with gamma-aminobutyric-acid B receptor antibodies (GABABR-AE) have poor functional outcomes and high mortality, the prognosis of nonparaneoplastic cases has not been well studied. Patients with GABABR-AE from the French and the Dutch Paraneoplastic Neurologic Syndromes Reference Centers databases were retrospectively included and their data collected; the neurologic outcomes of paraneoplastic and nonparaneoplastic cases were compared. Immunoglobulin G (IgG) isotyping and human leukocyte antigen (HLA) genotyping were performed in patients with available samples. A total of 111 patients (44/111 [40%] women) were enrolled, including 84 of 111 (76%) paraneoplastic and 18 of 111 (16%) nonparaneoplastic cases (cancer status was undetermined for 9 patients). Patients presented with seizures (88/111 [79%]), cognitive impairment (54/111 [49%]), and/or behavioral disorders (34/111 [31%]), and 54 of 111 (50%) were admitted in intensive care unit (ICU). Nonparaneoplastic patients were significantly younger (median age 54 years [range 19-88] vs 67 years [range 50-85] for paraneoplastic cases, p < 0.001) and showed a different demographic distribution. Nonparaneoplastic patients more often had CSF pleocytosis (17/17 [100%] vs 58/78 [74%], p = 0.02), were almost never associated with KTCD16-abs (1/16 [6%] vs 61/70 [87%], p < 0.001), and were more frequently treated with second-line immunotherapy (11/18 [61%] vs 18/82 [22%], p = 0.003). However, no difference of IgG subclass or HLA association was observed, although sample size was small (10 and 26 patients, respectively). After treatment, neurologic outcome was favorable (mRS ≤2) for 13 of 16 (81%) nonparaneoplastic and 37 of 84 (48%) paraneoplastic cases (p = 0.03), while 3 of 18 (17%) and 42 of 83 (51%) patients had died at last follow-up (p = 0.008), respectively. Neurologic outcome no longer differed after adjustment for confounding factors but seemed to be negatively associated with increased age and ICU admission. A better survival was associated with nonparaneoplastic cases, a younger age, and the use of immunosuppressive drugs. Nonparaneoplastic GABABR-AE involved younger patients without associated KCTD16-abs and carried better neurologic and vital prognoses than paraneoplastic GABABR-AE, which might be due to a more intensive treatment strategy. A better understanding of immunologic mechanisms underlying both forms is needed.


  • Resective epilepsy surgery and its impact on depression in adults: a systematic review, meta-analysis, and implications for future research

    by Natalia Hernandez Poblete, Florian Gay, Francesco Salvo, Jean-Arthur Micoulaud-Franchi, Thomas Bienvenu, Julien Coelho, Jerome Aupy

    Background: How epilepsy surgery influences the bidirectional relationship of epilepsy and depression remains poorly defined.Method: For a better understanding of this question, we conducted a systematic review and meta-analysis of risk ratio on depression prevalence before and after epilepsy surgery, using Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. Three databases were comprehensively screened for all studies assessing depression before and after resective surgery in adult epileptic patients until 8 October 2022. Studies were included if depression was assessed before and after epilepsy surgery regardless of the time of follow-up. A total of 1917 studies were screened for eligibility and 91 full-texts up for inclusion; 35 studies were finally included, 25 studies and 2563 patients were included in main meta-analysis and 10 for exploratory analysis. Risk of bias was assessed using Risk Of Bias In Non-randomised Studies - of Interventions (ROBINS-I) from Cochrane. To derive the pooled depression rates before and after surgery, a meta-analysis with inversed-variance was performed using random-effects logistic models with Peto’s correction and a 95% CI. Heterogeneity was assessed with Cochran’s Q-test along with its derived measure of inconsistency I2.Results: Overall, the depression rates before and after resective epilepsy surgery were 0.70 (0.53 to 0.91) 95% CI, suggesting that the rate of depression at last follow-up evaluation tends to decrease after Resective Epilepsy Surgery (RES). Subgroup analysis suggest a positive long-term effect appears with a significant lower rates of depression already 6 months (0.61 (0.38 to 0.98)), after surgery which is maintained over time after 1 year (0.53 (0.31 to 0.90)), and after 2 years (0.62 (0.42 to 0.92)).Conclusion: This important finding should be taken in consideration before resective surgery for drug-resistant epilepsies. However, prospective studies should be conducted to characterise which patient, at the individual level, might be at risk of de novo or worsening of depression.PROSPERO registration number: CRD42022355386.